December 20, 2017
Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More
learn more
December 19, 2017
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the final analysis of its phase… Read More
learn more
December 18, 2017
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival… Read More
learn more
December 1, 2017
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central… Read More
learn more
